Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 5, 2011, Pages 1291-1304

  Carol, Hernan ^a   Boehm, Ingrid ^a   Reynolds, C Patrick ^b   Kang, Min H ^b   Maris, John M ^c   Morton, Christopher L ^d   Gorlick, Richard ^e   Kolb, E Anders ^f   Keir, Stephen T ^g   Wu, Jianrong ^d   Wozniak, Amy E ^d   Yang, Yu ^h   Manfredi, Mark ^h   Ecsedy, Jeffrey ^h   Wang, Jianmin ^d   Neale, Geoffrey ^d   Houghton, Peter J ⁱ   Smith, Malcolm A ^j   Lock, Richard B ^a  

^a University of New South Wales   (Australia)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^f NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h MILLENNIUM PHARMACEUTICALS INC   (United States)

ⁱ NATIONWIDE CHILDREN S HOSPITAL   (United States)

^j NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

Developmental therapeutics; MLN8237; Pediatric cancer; Preclinical testing

Indexed keywords

ALISERTIB; MESSENGER RNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; AURORA KINASE A GENE; B CELL LEUKEMIA; CANCER CELL CULTURE; CANCER INHIBITION; CHILDHOOD CANCER; CONTROLLED STUDY; COPY NUMBER VARIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE DOSAGE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEURINOMA; MARKER GENE; MAXIMUM PLASMA CONCENTRATION; MITOSIS INDEX; MOUSE; NEPHROBLASTOMA; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SINGLE DRUG DOSE; SOLID TUMOR; T CELL LEUKEMIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR XENOGRAFT;

ANIMALS; AZEPINES; CELL LINE, TUMOR; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; GENE DOSAGE; HUMANS; MICE; MICE, SCID; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PYRIMIDINES;

EID: 82455192242     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1618-8     Document Type: Article

References (46)

1. D Hanahan RA Weinberg 2000 The hallmarks of cancer Cell 100 1 57 70 10647931 10.1016/S0092-8674(00)81683-9 1:CAS:528:DC%2BD3cXks1CktA%3D%3D (Pubitemid 30046295)
2. B Weaver D Cleveland 2005 Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death Cancer Cell 8 1 7 12 16023594 10.1016/j.ccr.2005.06.011 1:CAS:528:DC%2BD2MXntVejs78%3D (Pubitemid 40991810)
3. JR Jackson DR Patrick MM Dar PS Huang 2007 Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 7 2 107 117 17251917 10.1038/nrc2049 1:CAS:528:DC%2BD2sXotFOjtA%3D%3D (Pubitemid 46160987)
4. U Vijapurkar W Wang R Herbst 2007 Potentiation of kinesin spindle protein inhibitor-induced cell death by modulation of mitochondrial and death receptor apoptotic pathways Cancer Res 67 1 237 245 17210704 10.1158/0008-5472.CAN-06- 2406 1:CAS:528:DC%2BD2sXisFSnug%3D%3D (Pubitemid 46142780)
5. MC Henderson YJ Shaw H Wang H Han LH Hurley G Flynn RT Dorr DD Von Hoff 2009 UA62784, a novel inhibitor of centromere protein E kinesin-like protein Mol Cancer Ther 8 1 36 44 19139111 10.1158/1535-7163.MCT-08-0789 1:CAS:528:DC%2BD1MXjvFSluw%3D%3D
6. L Garuti M Roberti G Bottegoni 2009 Small molecule aurora kinases inhibitors Curr Med Chem 16 16 1949 1963 19519375 10.2174/092986709788682227 1:CAS:528:DC%2BD1MXnt1Ggsrk%3D
7. SL Warner PJ Gray DD Von Hoff 2006 Tubulin-associated drug targets: aurora kinases, Polo-like kinases, and others Semin Oncol 33 4 436 448 16890798 10.1053/j.seminoncol.2006.04.007 1:CAS:528:DC%2BD28XpsVersbw%3D (Pubitemid 44142740)
8. DO Cowley JA Rivera-Perez M Schliekelman YJ He TG Oliver L Lu R O'Quinn ED Salmon T Magnuson T Van Dyke 2009 Aurora-A kinase is essential for bipolar spindle formation and early development Mol Cell Biol 29 4 1059 1071 19075002 10.1128/MCB.01062-08 1:CAS:528:DC%2BD1MXisF2mtbw%3D
9. DR Wysong A Chakravarty K Hoar JA Ecsedy 2009 The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents Cell Cycle 8 6 876 888 19221504 10.4161/cc.8.6.7897 1:CAS:528:DC%2BD1MXlvFWisL8%3D
10. G Vader SM Lens 2008 The Aurora kinase family in cell division and cancer Biochim Biophys Acta 1786 1 60 72 18662747 1:CAS:528:DC%2BD1cXhtFCktrfE
11. L Macurek A Lindqvist D Lim MA Lampson R Klompmaker R Freire C Clouin SS Taylor MB Yaffe RH Medema 2008 Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery Nature 455 7209 119 123 18615013 10.1038/nature07185 1:CAS:528:DC%2BD1cXhtVKrsbbK
12. A Seki JA Coppinger CY Jang JR Yates G Fang 2008 Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry Science 320 5883 1655 1658 10.1126/science.1157425 18566290 10.1126/science. 1157425 1:CAS:528:DC%2BD1cXnt1Oju7g%3D (Pubitemid 351931258)
13. H Zhou J Kuang L Zhong W Kuo J Gray A Sahin B Brinkley S Sen 1998 Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation Nat Genet 20 2 189 193 9771714 10.1038/2496 1:CAS:528: DyaK1cXms1eis78%3D (Pubitemid 28455454)
14. O Gautschi J Heighway PC Mack PR Purnell PN Lara Jr DR Gandara 2008 Aurora kinases as anticancer drug targets Clin Cancer Res 14 6 1639 1648 18347165 10.1158/1078-0432.CCR-07-2179 1:CAS:528:DC%2BD1cXjtlejtrY%3D (Pubitemid 351471713)
15. P Carpinelli J Moll 2008 Aurora kinase inhibitors: identification and preclinical validation of their biomarkers Exp Opin Therap Targets 12 1 69 80 10.1517/14728222.12.1.69 10.1517/14728222.12.1.69 1:CAS:528:DC%2BD2sXhsVagsLbM (Pubitemid 351247163)
16. MG Manfredi JA Ecsedy KA Meetze SK Balani O Burenkova W Chen KM Galvin KM Hoar JJ Huck PJ LeRoy ET Ray TB Sells B Stringer SG Stroud TJ Vos GS Weatherhead DR Wysong M Zhang JB Bolen CF Claiborne 2007 Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase PNAS 104 10 4106 4111 10.1073/pnas.0608798104 17360485 10.1073/pnas.0608798104 1:CAS:528:DC%2BD2sXjt12nu7o%3D (Pubitemid 47181586)
17. Q Liu S Kaneko L Yang RI Feldman SV Nicosia J Chen JQ Cheng 2004 Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215 J Biol Chem 279 50 52175 52182 10.1074/jbc.M406802200 15469940 10.1074/jbc.M406802200 1:CAS:528:DC%2BD2cXhtVCktbfO (Pubitemid 39656591)
18. C Crosio G Fimia R Loury M Kimura Y Okano H Zhou S Sen C Allis P Sassone-Corsi 2002 Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian aurora kinases Mol Cell Biol 22 3 874 885 11784863 10.1128/MCB.22.3.874-885.2002 1:CAS:528:DC%2BD38Xmt12nsA%3D%3D (Pubitemid 34053065)
19. JM Maris 2009 Unholy matrimony: aurora A and N-Myc as malignant partners in neuroblastoma Cancer Cell 15 1 5 6 19111875 10.1016/j.ccr.2008.12.008 1:CAS:528:DC%2BD1MXptVGqtg%3D%3D
20. T Otto S Horn M Brockmann U Eilers L Schuttrumpf N Popov AM Kenney JH Schulte R Beijersbergen H Christiansen B Berwanger M Eilers 2009 Stabilization of N-Myc is a critical function of aurora A in human neuroblastoma Cancer Cell 15 1 67 78 19111882 10.1016/j.ccr.2008.12.005 1:CAS:528:DC%2BD1MXptVKjsw%3D%3D
21. AA Dar A Belkhiri J Ecsedy A Zaika W El-Rifai 2008 Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells Cancer Res 68 21 8998 9004 18974145 10.1158/0008-5472.CAN-08-2658 1:CAS:528: DC%2BD1cXhtlSkurzE
22. J-e Yao M Yan Z Guan C-b Pan L-p Xia C-x Li L-h Wang Z-j Long Y Zhao M-w Li F-m Zheng J Xu D-j Lin Q Liu 2009 Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival Mol Cancer 8 1 95 19891769 10.1186/1476-4598-8-95
23. JM Maris CL Morton R Gorlick EA Kolb R Lock H Carol ST Keir CP Reynolds MH Kang J Wu MA Smith PJ Houghton 2010 Initial testing of the aurora kinase a inhibitor MLN8237 by the pediatric preclinical testing program (PPTP) Pediatr Blood Cancer 55 1 26 34 20108338
24. T Frgala O Kalous RT Proffitt CP Reynolds 2007 A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations Mol Cancer Ther 6 3 886 897 17363483 10.1158/1535-7163.MCT-04-0331 1:CAS:528:DC%2BD2sXivV2ntbg%3D (Pubitemid 46554558)
25. PJ Houghton CL Morton EA Kolb R Lock H Carol CP Reynolds N Keshelava JM Maris ST Keir J Wu MA Smith 2008 Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program Pediatr Blood Cancer 50 1 37 45 17420992 10.1002/pbc.21214 (Pubitemid 350234263)
26. Kang M, Smith MA, Morton CL, Keshelava N, Houghton PJ, Reynolds CP (2011) National cancer institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr Blood Cancer 56:239-249
27. HS Friedman OM Colvin SX Skapek SM Ludeman GB Elion SC Schold Jr PF Jacobsen LH Muhlbaier DD Bigner 1988 Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents Cancer Res 48 15 4189 4195 3390813 1:CAS:528: DyaL1cXlsVais74%3D
28. C Graham C Tucker J Creech E Favours CA Billups T Liu M Fouladi BB Freeman 3rd CF Stewart PJ Houghton 2006 Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo Clin Cancer Res 12 1 223 234 16397046 10.1158/1078-0432.CCR-05-1225 1:CAS:528:DC%2BD28Xht1Gksw%3D%3D (Pubitemid 43166198)
29. Peterson JK, Tucker C, Favours E, Cheshire PJ, Creech J, Billups CA, Smykla R, Lee FY, Houghton PJ (2005) In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res 11(19 Pt 1):6950-6958 (Pubitemid 41428753)
30. NL Liem RA Papa CG Milross MA Schmid M Tajbakhsh S Choi CD Ramirez AM Rice M Haber MD Norris KL MacKenzie RB Lock 2004 Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies Blood 103 10 3905 3914 14764536 10.1182/blood-2003-08-2911 1:CAS:528:DC%2BD2cXjvF2hsrw%3D (Pubitemid 38596312)
31. PJ Houghton CL Morton C Tucker D Payne E Favours C Cole R Gorlick EA Kolb W Zhang R Lock H Carol M Tajbakhsh CP Reynolds JM Maris J Courtright ST Keir HS Friedman C Stopford J Zeidner J Wu T Liu CA Billups J Khan S Ansher J Zhang MA Smith 2007 The pediatric preclinical testing program: description of models and early testing results Pediatr Blood Cancer 49 7 928 940 17066459 10.1002/pbc.21078 (Pubitemid 350022448)
32. X Zhao C Li JG Paez K Chin PA Janne TH Chen L Girard J Minna D Christiani C Leo JW Gray WR Sellers M Meyerson 2004 An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays Cancer Res 64 9 3060 3071 15126342 10.1158/0008-5472.CAN-03-3308 1:CAS:528:DC%2BD2cXjs1ehtr4%3D (Pubitemid 38581405)
33. S Pounds C Cheng C Mullighan SC Raimondi S Shurtleff JR Downing 2009 Reference alignment of SNP microarray signals for copy number analysis of tumors Bioinformatics 25 3 315 321 10.1093/bioinformatics/btn624 19052058 10.1093/bioinformatics/btn624 1:CAS:528:DC%2BD1MXhtlOlsrs%3D
34. AB Olshen ES Venkatraman R Lucito M Wigler 2004 Circular binary segmentation for the analysis of array-based DNA copy number data Biostatistics 5 4 557 572 10.1093/biostatistics/kxh008 15475419 10.1093/biostatistics/kxh008 (Pubitemid 41180205)
35. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5(10):R80. doi: 10.1186/gb-2004-5-10-r80
36. G Neale X Su CL Morton D Phelps R Gorlick RB Lock CP Reynolds JM Maris HS Friedman J Dome J Khoury TJ Triche RC Seeger R Gilbertson J Khan MA Smith PJ Houghton 2008 Molecular characterization of the pediatric preclinical testing panel Clin Cancer Res 14 14 4572 4583 10.1158/1078-0432.ccr-07-5090 18628472 10.1158/1078-0432.CCR-07-5090 1:CAS:528:DC%2BD1cXosFGitb0%3D
37. K Wakahara T Ohno M Kimura T Masuda S Nozawa T Dohjima T Yamamoto A Nagano G Kawai A Matsuhashi M Saitoh I Takigami Y Okano K Shimizu 2008 EWS-Fli1 Up-regulates expression of the aurora A and Aurora B Kinases Mol Cancer Res 6 12 1937 1945 10.1158/1541-7786.mcr-08-0054 19074838 10.1158/1541-7786.MCR-08-0054 1:CAS:528:DC%2BD1cXhsV2iu7bL
38. X Shang SM Burlingame MF Okcu N Ge HV Russell RA Egler RD David SA Vasudevan J Yang JG Nuchtern 2009 Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma Mol Cancer Ther 8 8 2461 2469 10.1158/1535-7163.mct-08-0857 19671766 10.1158/1535-7163.MCT-08-0857 1:CAS:528:DC%2BD1MXpvFCmsL4%3D
39. T Hirota N Kunitoku T Sasayama T Marumoto D Zhang M Nitta K Hatakeyama H Saya 2003 Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells Cell 114 5 585 598 13678582 10.1016/S0092-8674(03)00642-1 1:CAS:528:DC%2BD3sXntlalt7c%3D (Pubitemid 37159255)
40. H Katayama WR Brinkley S Sen 2003 The Aurora kinases: role in cell transformation and tumorigenesis Cancer Metastasis Rev 22 4 451 464 12884918 10.1023/A:1023789416385 (Pubitemid 36791899)
41. S Sen H Zhou RD Zhang DS Yoon F Vakar-Lopez S Ito F Jiang D Johnston HB Grossman AC Ruifrok RL Katz W Brinkley B Czerniak 2002 Amplification/ overexpression of a mitotic kinase gene in human bladder cancer J Natl Cancer Inst 94 17 1320 1329 12208897 10.1093/jnci/94.17.1320 1:CAS:528: DC%2BD38XntVGqur8%3D
42. JR Bischoff L Anderson Y Zhu K Mossie L Ng B Souza B Schryver P Flanagan F Clairvoyant C Ginther CS Chan M Novotny DJ Slamon GD Plowman 1998 A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers EMBO J 17 11 3052 3065 9606188 10.1093/emboj/17.11.3052 1:CAS:528:DyaK1cXjvFeisro%3D (Pubitemid 28254378)
43. S Anand S Penrhyn-Lowe AR Venkitaraman 2003 AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol Cancer Cell 3 1 51 62 12559175 10.1016/S1535-6108(02)00235-0 1:CAS:528:DC%2BD3sXhtFamt7Y%3D (Pubitemid 37443890)
44. DA Sloane MZ Trikic MLH Chu MBAC Lamers CS Mason I Mueller WJ Savory DH Williams PA Eyers 2010 Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237 ACS Chem Biol 5 6 563 576 10.1021/cb100053q 20426425 10.1021/cb100053q 1:CAS:528:DC%2BC3cXlvVaktbs%3D
45. Dees EC, Infante JR, Burris HA, Astsaturov IA, Stinchcombe T, Liu H, Galvin K, Venkatakrishnan K, Fingert HJ, Cohen RB (2010) Phase I study of the investigational drug MLN8237, an Aurora A kinase (AAK) inhibitor, in patients (pts) with solid tumors. J Clin Oncol 28(15 suppl) (May 20 Supplement), Abstr #3010
46. R Giet DM Glover 2001 Drosophila aurora B kinase is required for histone H3 phosphorylation and condensin recruitment during chromosome condensation and to organize the central spindle during cytokinesis J Cell Biol 152 4 669 682 11266459 10.1083/jcb.152.4.669 1:CAS:528:DC%2BD3MXhtlGmtrc%3D (Pubitemid 34280153)